Pfenex Inc. (NYSEMKT:PFNX) Files An 8-K Results of Operations and Financial Condition

Pfenex Inc. (NYSEMKT:PFNX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On August9, 2017, Pfenex Inc. issued a press release reporting its financial results for the quarter ended June30, 2017. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 2.02 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1 Press Release dated August9, 2017.


Pfenex Inc. Exhibit
EX-99.1 2 d440257dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   FOR IMMEDIATE RELEASE Pfenex Reports Second Quarter 2017 Results and Provides Business Update SAN DIEGO,…
To view the full exhibit click here

About Pfenex Inc. (NYSEMKT:PFNX)

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

An ad to help with our costs